STAT+: In wake of boy’s death, gene editing experts dissect Huidagene’s decisions
Summary
Gene editing experts are examining the technical choices made by Huidagene after a boy died during treatment for Duchenne muscular dystrophy. They question whether the company's attempted improvements addressed the risks of a strategy that U.S. developers have largely abandoned.
The boy's death has shifted scrutiny from the promise of the therapy to the judgment
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The case could influence whether high-risk gene therapies are refined, delayed, or rejected as companies pursue treatments for fatal diseases.